Supplementary Material for: Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

  • Francesca Conway (Contributor)
  • James Tonkin (Contributor)
  • Arschang Valipour (Contributor)
  • Christophe Pison (Contributor)
  • Christian Schumann (Contributor)
  • Peter Bonta (Contributor)
  • Romain Kessler (Contributor)
  • Wolfgang Gesierich (Contributor)
  • Kaid Darwiche (Contributor)
  • Bernd Lamprecht (Contributor)
  • Dirk Skowasch (Contributor)
  • Philip J. Johnson (Contributor)
  • Dirk-Jan Slebos (Contributor)
  • Pallav L. Shah (Contributor)
  • Lamprecht B. (Creator)

Dataset

Description

Background: Targeted Lung Denervation (TLD) is a potential new therapy for COPD. Radiofrequency energy is bronchoscopically delivered to the airways to disrupt pulmonary parasympathetic nerves, to reduce bronchoconstriction, mucus hypersecretion, and br...
Date made available2022
PublisherKarger Publishers

Access Dataset

Cite this